Overview

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
TG Therapeutics, Inc.
Collaborator:
SCRI Development Innovations, LLC